# Sorafenib Long Term Extension Program

> **NCT00625378** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 206 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00625378
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-21
- **Primary completion:** 2021-09-24
- **Final completion:** 2021-09-24
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2022-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625378, "Sorafenib Long Term Extension Program". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00625378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*